MASP2 and COVID-19: Currently, only anecdotal reports of the successful treatment of seriously ill patients with COVID-19 employing the MASP-2 inhibitor Narsoplimab (44), the C5 inhibitor Eculizumab (45–47) or the C3 inhibitor AMY-101 (48) have been published.